pharma · HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER · Advanced HER2-Expressing Solid Tumors. · BOLT
Bolt Biotherapeutics
Bolt Biotherapeutics clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Redwood City, USA
- Founded
- 2015
- Employees
- 51
- Programs
- 6
- Drugs
- 4
- Patents
- 7
Bolt Biotherapeutics projects
6 ClinicalTrials.gov programs sponsored by Bolt Biotherapeutics.
Bolt Biotherapeutics has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
BBI-20201001
Bolt Biotherapeutics
Advanced HER2-Expressing Solid Tumors.
1 trial -
BDC-1001
Bolt Biotherapeutics
HER2-positive Solid Tumors
1 trial -
BDC-1001
Bolt Biotherapeutics
Metastatic Breast Cancer
1 trial -
BDC-1001, PERTUZUMAB
Bolt Biotherapeutics
HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2–POSITIVE METASTATIC BREAST CANCER
1 trial -
BDC-4182
Bolt Biotherapeutics
Gastric Cancer Adenocarcinoma Metastatic
1 trial -
BDC-3042
Bolt Biotherapeutics
Triple Negative Breast Cancer
1 trial
Frequently asked questions
How many clinical projects does Bolt Biotherapeutics have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.